Searching for new molecular targets for therapy of cancer and AIDS: characterization by 2D protein gel electrophoresis (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Searching for new molecular targets for therapy of cancer and AIDS: characterization by 2D protein gel electrophoresis (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 35:A3656 1994. Unique Identifier : AIDSLINE ICDB/95605341
Buolamwini JK; Myers TG; Scudiero DA; Grever MR; Anderson NL; Weinstein JN; Developmental Therapeutics Program, DCT, NCI, Bethesda, MD 20892

Abstract: A large data base of drug sensitivity results has been generated in the National Cancer Institute's (NCI) in vitro anticancer drug screen with 60 human cancer cell lines (representing 9 organs of origin). More than 10,000 compounds are tested each year. One advantage of the cell line screen over a pure target assay is that the former affords the opportunity to probe many mechanisms of differential sensitivity simultaneously (Weinstein et al, Science 258:447, 1992) and to search for new molecular targets. We are using high resolution 2D protein gel electrophoresis to analyze differences among the cell lines with regard to molecular targets and to search for new ones. About 1000 protein species have been resolved from whole cell lysates, using the ISODALT 2D electrophoresis system. These proteins will be further characterized and the information combined with patterns of differential cell line drug sensitivity. Subsequent perturbation studies will be used to search for additional molecular targets. A similar electrophoresis analysis is being undertaken for the cell lines used in the NCI's in vitro anti-AIDS drug screen. The molecular target information base derived from these studies is providing a useful tool for drug design and discovery.

Keywords: Acquired Immunodeficiency Syndrome/*THERAPY Drug Screening Assays, Antitumor *Electrophoresis, Gel, Two-Dimensional Gene Therapy Human Neoplasms/*THERAPY ABSTRACT
950330
M9530828

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .